Evidence map›Paper›PMID 42704611›Full record

ReviewAnnals of nuclear medicine2026

The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.

Yihong Chen, Yaofeng Xiao, Zhe Zhang, Maohua Rao, Zhenyu Yang, Zi Wang, Yu Zhang, Yue Feng, Liang Cai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yihong ChenDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.ORCID http://orcid.org/0009-0002-2979-648X
Yaofeng XiaoDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Zhe ZhangDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Maohua RaoDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Zhenyu YangDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Zi WangDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Yu ZhangDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Yue FengDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China.
Liang CaiDepartment of Nuclear medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District, Chongqing, 400010, China. 306663@hospital.cqmu.edu.cn.

Funding

Chongqing Natural Science Foundation CSTB2024NSCQMSX0211
6 · The paper itself

Abstract

Sarcomas represent a heterogeneous group of malignant neoplasms arising from mesenchymal tissue and remain challenging to diagnose and treat. Fibroblast activation protein (FAP), highly expressed in the tumor microenvironment, has emerged as a attractive target for molecular imaging. This review aims to evaluate the role of fibroblast activation protein inhibitors (FAPI) in sarcoma diagnosis and therapy. Following PRISMA guidelines, we searched PubMed, Embase, and Web of Science for studies published between 2018 and 2025 investigating FAPI in sarcoma imaging or treatment. Diagnostic study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). Twelve studies comprising 398 patients met inclusion criteria. Six diagnostic studies (361 patients, 2,477 lesions) reported a pooled detection rate of 89.7% for all sarcoma lesions and 91.3% for distant metastases with FAPI positron emission tomography (PET), higher than [

Indexed as

Fibroblast activation protein inhibitorPositron emission tomographyRadionuclide therapySarcomaTheranostics

Identifiers

PMID42704611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.